Autopsy report · NCT03326258

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The study itself was Disapproved on 04/20/2018 and will not be moving forward.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 1, Phase 2
Sponsor: National Cancer Institute (NCI)
Sponsor type: US National Institutes of Health
Conditions: Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative; GPNMB Positive; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma
Interventions: Glembatumumab Vedotin; Ipilimumab; Laboratory Biomarker Analysis; Nivolumab; Pharmacological Study
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.